Xtrana to develop nucleic acid-based chlamydia test:
This article was originally published in Clinica
US company Xtrana is to develop a nucleic acid-based test for Chlamydia trachomatis using a Phase I grant from the US National Institutes of Health. The test, for use in the doctor's office or at a healthcare clinic, uses an isothermal method for amplification, eliminating the need for expensive and complex equipment such as thermocyclers, said the Denver, Colorado-based company. Xtrana added that the new test detected RNA from chlamydia and would therefore be more specific to live organisms than DNA-based tests or antibody/antigen tests.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.